mission clinical program gwg recommendations
play

MISSION Clinical Program GWG Recommendations Gil Sambrano Vice - PowerPoint PPT Presentation

MISSION Clinical Program GWG Recommendations Gil Sambrano Vice President, Portfolio Development and Review California Institute for Regenerative Medicine February 22, 2018 Clinical Stage Programs MISSION CLINICAL STAGE CLIN 1 CLIN 2 CLIN


  1. MISSION Clinical Program GWG Recommendations Gil Sambrano Vice President, Portfolio Development and Review California Institute for Regenerative Medicine February 22, 2018

  2. Clinical Stage Programs MISSION CLINICAL STAGE CLIN 1 CLIN 2 CLIN 3

  3. Scoring System for Clinical Applications MISSION § Score of “1” Exceptional merit and warrants funding. § Score of “2” Needs improvement and does not warrant funding at this time but could be resubmitted to address areas for improvement. § Score of “3” Sufficiently flawed that it does not warrant funding and the same project should not be resubmitted for at least 6 months . Applications are scored by all scientific members of the GWG with no conflict.

  4. CLIN2-10847: Phase 1 Clinical Trial of Therapy for Sickle Cell Disease Project Summary Haploidentical blood stem cell transplant Therapy Indication Adult patients with severe sickle cell disease Goal Complete a phase 1 clinical trial to assess safety and feasibility of achieving mixed chimerism $5,742,180 ($435,834 Co-funding) Funds Requested Maximum funds allowable for this category: $12,000,000

  5. CLIN2-10847: Phase 1 Clinical Trial of MISSION Therapy for Sickle Cell Disease GWG Recommendation: Exceptional merit and warrants funding GWG Votes Score 1 7 2 5 3 0 CIRM Team Recommendation: Fund (concur with GWG recommendation) Award Amount : $5,742,180* *Final award shall not exceed this amount and may be reduced contingent on CIRM’s final assessment of allowable costs and activities.

  6. CLIN1-10893: Preclinical Study of Natural Killer Cell Immunotherapy for Cancer Project Summary Natural killer cells derived from iPSC Therapy Indication Patients with advanced cancers Goal Complete IND-enabling studies and manufacturing processes for IND submission $5,649,684 ($1,979,405 Co-funding) Funds Requested Maximum funds allowable for this category: $4,000,000

  7. CLIN1-10893: Preclinical Study of Natural MISSION Killer Cell Immunotherapy for Cancer GWG Recommendation: Exceptional merit and warrants funding GWG Votes Score 1 7 2 5 3 0 CIRM Team Recommendation: Fund (concur with GWG recommendation) with reduction in budget Award Amount : $4,000,000* (Maximum allowed under new policy) *Final award shall not exceed this amount and may be reduced contingent on CIRM’s final assessment of allowable costs and activities.

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend